12-Jan-2026
Bank of America Securities Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP)
TipRanks (Tue, 13-Jan 6:07 AM ET)
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and NeoGenomics (NEO)
TipRanks (Mon, 12-Jan 8:20 PM ET)
CRISPR Therapeutics Highlights Pipeline Advances in Gene-Edited Therapies
TipRanks (Mon, 12-Jan 9:02 AM ET)
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
Globe Newswire (Mon, 12-Jan 8:36 AM ET)
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Mon, 5-Jan 8:30 AM ET)
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
Globe Newswire (Tue, 16-Dec 12:00 PM ET)
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
PRNewswire (Tue, 9-Dec 11:58 AM ET)
The Biotech Sector is Seeing a Major Boost From Programmable Cell Therapies in Chronic Disease Care
Globe Newswire (Wed, 19-Nov 10:06 AM ET)
Market Chameleon (Mon, 10-Nov 3:12 AM ET)
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Globe Newswire (Mon, 10-Nov 8:00 AM ET)
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Crispr Therapeutics Ag - Common Shares trades on the NASDAQ stock market under the symbol CRSP.
As of January 12, 2026, CRSP stock price climbed to $55.30 with 1,845,497 million shares trading.
CRSP has a beta of 1.78, meaning it tends to be more sensitive to market movements. CRSP has a correlation of 0.28 to the broad based SPY ETF.
CRSP has a market cap of $5.27 billion. This is considered a Mid Cap stock.
Last quarter Crispr Therapeutics Ag - Common Shares reported $889,000 in Revenue and -$1.17 earnings per share. This fell short of revenue expectation by $-7 million and exceeded earnings estimates by $.13.
In the last 3 years, CRSP traded as high as $91.10 and as low as $30.04.
The top ETF exchange traded funds that CRSP belongs to (by Net Assets): ARKK, IWM, ARKG, XBI, VXF.
CRSP has outperformed the market in the last year with a price return of +39.3% while the SPY ETF gained +21.0%. However, in the short term, CRSP had mixed performance relative to the market. It has underperformed in the last 3 months, returning -24.3% vs +6.8% return in SPY. But in the last 2 weeks, CRSP shares have fared better than the market returning +2.5% compared to SPY +1.1%.
CRSP support price is $52.22 and resistance is $55.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRSP shares will trade within this expected range on the day.